Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Yhp-743, a noval parp1/2 inhibitor for treatment of human triple-negative breast cancer with brca deficiency

  • At: 2014 FIP Congress in PSWC, Melbourne (Australia)
  • Type: Poster
  • By: JI, Ming (Beijing, China)
  • Abstract:

    I.Background
    Triple-negative breast cancers (TNBC) occur more frequently in women, and the only available treatment for TNBC is chemotherapy. Targeting the nuclear enzyme Poly (ADP-ribose) Polymerase (PARP) represents a novel approach to treatment of TNBC. YHP-743, a potent small molecule inhibitor of PARP1/2, is being developed for treatment of..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses